Adenoviral Conjunctivitis
9
0
0
4
Key Insights
Highlights
Success Rate
57% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
33.3%
3 terminated out of 9 trials
57.1%
-29.4% vs benchmark
22%
2 trials in Phase 3/4
75%
3 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (9)
Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Viral Conjunctivitis
OKG-0301 for the Treatment of Acute Adenoviral Conjunctivitis
Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine (PVP-I) and Placebo
Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Placebo
Reducing Adenoviral Patient Infected Days
Efficacy and Safety of Iota-Carrageenan Eye Drops (NCX-4240)
Efficacy and Safety of NVC-422 in the Treatment of Adenoviral Conjunctivitis
An Evaluation of the Efficacy and Safety of AL-46383A Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis
Evaluation of a Rapid Screening Test for Detection of Adenovirus in Tears